[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Mittal R, Al Awadi S, Sahar O, Behbehani AM: Ewing's sarcoma as second malignant neoplasm after retinoblastoma: a case report. Med Princ Pract; 2008;17(1):84-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma as second malignant neoplasm after retinoblastoma: a case report.
  • OBJECTIVES: To report a case of a child with the hereditary form of unilateral retinoblastoma (RB), who developed Ewing's sarcoma of the right fibula 3 years after the enucleation of the right eye.
  • The patient received chemotherapy and diode laser thermotherapy in Kuwait and the UK.
  • After 3 years, he was investigated for a small swelling in his right lower leg.
  • He was treated with chemotherapy, surgery (complete excision of the fibula) and high-dose chemotherapy followed by autologous stem cell transplantation.
  • The child is now nearly 2 years after completing the treatment and is disease free.
  • CONCLUSIONS: This case confirms the increased risk of a second malignant neoplasm (SMN) in children with hereditary RB.
  • [MeSH-major] Bone Neoplasms / diagnosis. Fibula. Neoplasms, Second Primary / diagnosis. Retinal Neoplasms / diagnosis. Retinoblastoma / diagnosis. Sarcoma, Ewing / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Diagnosis, Differential. Eye Enucleation. Humans. Infant. Male. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 18059108.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


2. Nickerson HJ, Silberman T, Jacobsen FS, Krawisz BR, Maki HS, Arndt CA: Alveolar soft-part sarcoma responsive to intensive chemotherapy. J Pediatr Hematol Oncol; 2004 Apr;26(4):233-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar soft-part sarcoma responsive to intensive chemotherapy.
  • Alveolar soft-part sarcoma (ASPS) is a very rare malignant tumor, usually of the extremities, and is seen most often in adolescents and young adults.
  • Surgical excision of the primary and pulmonary metastases has resulted in prolonged survival in some patients, but adjuvant radiation and/or chemotherapy are generally thought to be ineffective.
  • Following intensive multiagent chemotherapy, pulmonary metastases showed in vivo evidence of tumor death.
  • The patient has remained disease-free for 10 years following treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Doxorubicin / administration & dosage. Female. Humans. Leg. Mesna / administration & dosage. Neoplasm Metastasis / pathology. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15087950.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna
  •  go-up   go-down


3. Yamamoto Y, Goto M, Okamoto T, Tomita I, Murayama A, Sawa M, Noguchi Y, Hoshikawa Y, Shimizu A: [Chemotherapy-naïve advanced malignant fibrohistiocytoma presenting IVC syndrome case report]. Gan To Kagaku Ryoho; 2010 Feb;37(2):355-7
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy-naïve advanced malignant fibrohistiocytoma presenting IVC syndrome case report].
  • The case was a 77-year-old male with swelling of his right leg.
  • Computed tomography (CT) and 3 dimensional CT showed an 8-cm tumor on the IVC, partially replacing iliac vessels and invading the psoas muscle.
  • A diagnosis of malignant fibrohistiocytoma was made by pathological examination of biopsied specimens at exploratory laparotomy.
  • Five courses of combination chemotherapy of ifosfamide (IFM) and doxorubicin (DXR) resulted in PR.
  • Edema of the lower leg and hydronephrosis were both alleviated.
  • Another 5 courses of chemotherapy with epirubicin and IFM were added.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / therapeutic use. Histiocytoma, Malignant Fibrous / complications. Histiocytoma, Malignant Fibrous / drug therapy. Ifosfamide / therapeutic use. Superior Vena Cava Syndrome / etiology. Vena Cava, Inferior / pathology
  • [MeSH-minor] Aged. Biopsy. Humans. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154502.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


Advertisement
4. Tanoue K, Sanada J, Kayano T, Tanaka H, Terashi T: [Malignant lymphoma with various cardiac manifestations: a case report]. J Cardiol; 2002 Sep;40(3):117-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma with various cardiac manifestations: a case report].
  • A 49-year-old woman presented with malignant lymphoma manifesting as dyspnea, palpitation and leg edema.
  • The diagnosis was malignant lymphoma(B-cell) based on lymph node biopsy.
  • Chemotherapy(CHOP) was performed under a suspected diagnosis of cardiac invasion of malignant lymphoma.
  • Immediately after chemotherapy, ECG showed complete atrioventricular block with sinus arrest, ventricular fibrillation and atrial fibrillation.
  • ECG was normalized after 2 weeks on chemotherapy.
  • However, she died of recurrence of malignant lymphoma on day 116.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Administration Schedule. Electrocardiography. Female. Humans. Middle Aged. Neoplasm Invasiveness. Pericardial Effusion / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12325461.001).
  • [ISSN] 0914-5087
  • [Journal-full-title] Journal of cardiology
  • [ISO-abbreviation] J Cardiol
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Neumann A, Karbach J, Atmaca A, Jäger E: [Long-term remission of malignant melanoma stage IV after antigen-specific immunotherapy]. Med Klin (Munich); 2010 Apr;105(4):273-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term remission of malignant melanoma stage IV after antigen-specific immunotherapy].
  • This case report describes the clinical course of a patient with progressing metastatic melanoma (M1a) under standard chemotherapy, followed by long-term partial remission of disease under treatment with experimental, specific immunotherapy.
  • [MeSH-major] Antigens, Neoplasm / immunology. Cancer Vaccines / therapeutic use. Epitopes / immunology. Immunotherapy / methods. Leg. Melanoma / drug therapy. Neoplasm Proteins / immunology. Skin Neoplasms / drug therapy. Survivors
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. CD4-Positive T-Lymphocytes / drug effects. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / drug effects. CD8-Positive T-Lymphocytes / immunology. Chemotherapy, Adjuvant. Disease Progression. Female. Follow-Up Studies. Humans. Hypersensitivity, Delayed / immunology. Injections, Intradermal. Lymphatic Metastasis / pathology. Melanoma-Specific Antigens. Middle Aged. Neoplasm Staging. Palliative Care

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 May 15;86(4):538-47 [10797269.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):54-62 [8690525.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14453-8 [16984998.001]
  • [Cites] Cancer Sci. 2009 Nov;100(11):2014-21 [19719775.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):725-9 [8642276.001]
  • (PMID = 20455048.001).
  • [ISSN] 1615-6722
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Epitopes; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


6. Shiraishi H, Motomura M, Iwanaga H, Tsujino A, Nishiura Y, Shirabe S, Nakamura T, Yoshimura T: [Successful treatment in a patient with a focal form of stiff-person syndrome using plasma exchange and intravenous immunoglobulin therapy]. Rinsho Shinkeigaku; 2002 Aug;42(8):766-70
Genetic Alliance. consumer health - Stiff person syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment in a patient with a focal form of stiff-person syndrome using plasma exchange and intravenous immunoglobulin therapy].
  • We report a 42-year-old female with continuous muscle stiffness and painful muscle spasms of the right leg.
  • The symptoms developed suddenly and worsened over the week after onset.
  • At hospitalization, the right leg had a fixed posture of extension and the foot was plantar-flexed and internally rotated.
  • Neurological examination revealed hyperreflexia of the right knee with positive Chaddock's sign, and stiffness and painful spasms located in the right leg, exaggerated by sudden auditory and tactile stimuli or by emotional stress.
  • There were no signs of rigidity in the left leg, upper extremities, or truncal muscles.
  • High titers of anti-glutamic decarboxylase (GAD) antibodies were detected in serum (140,000 U/ml) and cerebrospinal fluid (1,347 U/ml), confirming that the patient suffered from stiff-leg syndrome.
  • Systemic evaluation revealed no malignant neoplasm, but revealed euthyroid Hashimoto's disease.
  • Stiff-leg syndrome in this case was unresponsive to pharmacotherapy with diazepam and was unchanged for the first month of hospitalization.
  • Plasma exchange therapy alleviated the clinical symptoms and decreased the anti-GAD antibody titer.
  • After IVIg therapy, the symptoms and signs have dramatically disappeared to date but the titer of anti-GAD antibodies in serum recurred after an initial fall.
  • To our knowledge, this is the first case of stiff-leg syndrome in Japan.
  • [MeSH-major] Immunoglobulins, Intravenous / administration & dosage. Plasma Exchange. Stiff-Person Syndrome / therapy
  • [MeSH-minor] Adult. Autoantibodies / blood. Autoantibodies / cerebrospinal fluid. Biomarkers / blood. Biomarkers / cerebrospinal fluid. Female. Glutamate Decarboxylase / immunology. Humans. Leg. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701225.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers; 0 / Immunoglobulins, Intravenous; EC 4.1.1.15 / Glutamate Decarboxylase
  • [Number-of-references] 22
  •  go-up   go-down


7. Wessalowski R, Schneider DT, Mils O, Hannen M, Calaminus G, Engelbrecht V, Pape H, Willers R, Engert J, Harms D, Göbel U: An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Padiatr; 2003 Nov-Dec;215(6):303-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors.
  • BACKGROUND: Elevated temperatures of 40 - 44 degrees C increase the actions of various anticancer drugs including N-lost derivatives, cytotoxic antibiotics and platinum analoga.
  • Among these, 24 patients had extracranial non-testicular germ cell tumors and 15 patients soft tissue or chondrosarcomas.
  • INDICATION: locoregional relapse (n = 29) or unresectable tumor after neoadjuvant chemotherapy (n = 10).
  • Among these two groups, there were ten patients with poor response or progressive disease under primary or relapse chemotherapy.
  • Tumor site: pelvis (30), abdomen (4), head and neck (2), proximal leg (2) and lumbar spine (1).
  • CONCLUSION: TCH shows substantial therapeutic efficacy and facilitates complete tumor resection in 14 out of 28 operated patients.
  • Multimodal treatment including TCH, surgical resection and/or radiotherapy leads to sustained remission in the majority of patients with locoregional tumor recurrence.
  • The therapeutic effect is most pronounced, if TCH is administered at first relapse.
  • Therefore, a more valid assessment of treatment efficacy can only be made by a matched-pair comparison in cooperation with the clinical registers.
  • [MeSH-major] Abdominal Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Chondrosarcoma / therapy. Cisplatin / therapeutic use. Etoposide / therapeutic use. Germinoma / therapy. Head and Neck Neoplasms / therapy. Hyperthermia, Induced. Ifosfamide / therapeutic use. Lumbar Vertebrae. Pelvic Neoplasms / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy. Spinal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Infant. Karnofsky Performance Status. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Time Factors. Treatment Outcome


8. Iacobellis C, Olmeda A: The Ilizarov method in the treatment of malignant neoplasms of the tibia. Chir Organi Mov; 2004 Jul-Aug;89(3):245-50
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Ilizarov method in the treatment of malignant neoplasms of the tibia.
  • A total of 3 malignant neoplasms of the tibia are presented: 1 is a mesenchymal chondrosarcoma of the tibial pylon (male aged 14 years), and 2 are cases of squamous skin carcinoma of the leg with tibial infiltration (1 male and 1 female aged 32 and 64 years, respectively).
  • The regenerate obtained was slowly corticalized in the first patient, submitted to various cycles of chemotherapy during the course of distraction.
  • In the other two cases, which were not treated by chemotherapy during distraction, corticalization occurred over a shorter amount of time.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Arthrodesis. Bone Transplantation. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Osteogenesis, Distraction. Osteotomy. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Time Factors. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751591.001).
  • [ISSN] 0009-4749
  • [Journal-full-title] La Chirurgia degli organi di movimento
  • [ISO-abbreviation] Chir Organi Mov
  • [Language] eng; ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Fukuda A, Sato Y, Iwatsubo S, Komatsu H, Nishiura R, Fukudome K, Yamada K, Hara S, Fujimoto S, Kitamura K: [Minimal change nephrotic syndrome complicated with recurrence of malignant thymoma: an interesting case with remission due to steroid therapy of both nephrotic syndrome and thymoma]. Nihon Jinzo Gakkai Shi; 2009;51(2):130-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Minimal change nephrotic syndrome complicated with recurrence of malignant thymoma: an interesting case with remission due to steroid therapy of both nephrotic syndrome and thymoma].
  • A 65-year-old man was admitted to our hospital with abdominal fullness and leg edema in April 2005.
  • Diabetes mellitus and hypertension that had been diagnosed in 1990 were well-controlled with oral hypoglucemic drug.
  • He presented with malignant thymoma accompanied by multiple metastases in the right thoracic space in December 2000.
  • He was treated with total thymectomy, combined with chemotherapy (cisplatin + vinorelbin) and hyperthermia.
  • However, CT scans showed multiple recurrences of thymoma in December 2004 and abdominal fullness and leg edema appeared shortly thereafter.
  • He was diagnosed with minimal change nephrotic syndrome (MCNS) complicated with the recurrence of malignant thymoma.
  • Corticosteroid therapy was started, but dialysis was transiently required to protect against oliguric acute renal failure.
  • Three weeks after the initiation of steroid therapy, the proteinuria was improved to less than 1.0 g/day and renal function returned to within the normal range.
  • Subsequent corticosteroid combined with immunosuppressive therapy resulted in good control of his nephrotic syndrome (NS) without recurrence.
  • There have been a few case reports showing NS complicated with malignant thymoma.
  • Among these, several cases with MCNS occurred after thymectomy for malignant thymoma.
  • Interestingly, both the thymoma mass and high pre-treatment vascular endothelial growth factor (VEGF) levels decreased as NS improved with steroid therapy.
  • [MeSH-major] Neoplasm Recurrence, Local / complications. Neoplasm Recurrence, Local / drug therapy. Nephrosis, Lipoid / drug therapy. Nephrosis, Lipoid / etiology. Prednisolone / administration & dosage. Thymoma / complications. Thymoma / drug therapy. Thymus Neoplasms / complications. Thymus Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cyclosporine / administration & dosage. Drug Therapy, Combination. Humans. Immunosuppressive Agents / administration & dosage. Male. Treatment Outcome. Vascular Endothelial Growth Factor A

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378799.001).
  • [ISSN] 0385-2385
  • [Journal-full-title] Nihon Jinzo Gakkai shi
  • [ISO-abbreviation] Nihon Jinzo Gakkai Shi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Vascular Endothelial Growth Factor A; 83HN0GTJ6D / Cyclosporine; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


10. Dodd LG, Major N, Brigman B: Malignant giant cell tumor of soft parts. Skeletal Radiol; 2004 May;33(5):295-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant giant cell tumor of soft parts.
  • We describe the clinical, histologic and radiologic features of a case with malignant behavior.
  • The patient presented with a fungating skin and soft tissue mass and concurrent pulmonary nodules.
  • [MeSH-major] Giant Cell Tumors / pathology. Leg / pathology. Lung Neoplasms / diagnosis. Osteosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Biopsy / methods. Diagnosis, Differential. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Recurrence, Local. Rare Diseases / drug therapy. Rare Diseases / pathology. Rare Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):248-56 [10680893.001]
  • [Cites] J Pathol. 1972 May;107(1):27-39 [4262633.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):736-47 [7226022.001]
  • [Cites] Cancer. 1972 Jun;29(6):1518-29 [5031245.001]
  • [Cites] Am J Dermatopathol. 1989 Jun;11(3):197-201 [2658646.001]
  • [Cites] Mod Pathol. 1999 Sep;12 (9):894-902 [10496598.001]
  • [Cites] Am J Surg. 1978 Jul;136(1):102-6 [277073.001]
  • [Cites] Cancer. 1977 Jul;40(1):244-53 [195704.001]
  • (PMID = 14997349.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Zawitkowska-Klaczyńska J, Katski K, Woźniak M, Kowalczyk JR: Characteristics and outcome of children with primary soft tissue sarcomas of extremities. Med Wieku Rozwoj; 2004 Apr-Jun;8(2 Pt 1):169-74
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcome of children with primary soft tissue sarcomas of extremities.
  • OBJECTIVES: To determine the characteristics and outcome or patients with primary soft tissue sarcomas of extremities in children.
  • MATERIAL AND METHODS: Thirty-six patients treated for soft tissues sarcomas were enrolled into the study.
  • Features analysed: the incidence of soft tissues sarcoma of extremities, the time from first clinical symptoms to making the diagnosis, the primary site of tumour; histopathologic type of tumour, stage of disease, methods and results of the treatment.
  • RESULTS: The time From first symptoms to making the diagnosis was 5.4 months (mean).
  • Histopathologic types: synovial sarcoma in 4 patients, malignant haemangiopericytoma in 2, rhabdomyosarcoma in 2, sarcoma myogenes in 1, primitive neuroectodermal tumour in l.
  • Patients underwent treatment according to the soft tissue sarcoma protocols.
  • Results of treatment: first complete remission was observed in 7 patients; second complete remission in 1, one patient is on postoperative treatment.
  • Combined treatment achieves full remission in the majority of patients with soft tissues sarcomas localized within the limbs.
  • 2. In patients with large tumours (>5 cm) the treatment should to be started with inductive chemotherapy, and the surgery should be postponed.
  • 3. Early excision of the tumour should be considered in cases of small tumours (< 5 cm), when resection with wide margin of healthy tissues is possible, without deteriorating the function of the limb or cosmetic damage.
  • [MeSH-major] Arm. Leg. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Hemangiopericytoma / diagnosis. Hemangiopericytoma / therapy. Humans. Incidence. Male. Myosarcoma / diagnosis. Myosarcoma / therapy. Neoplasm Staging. Neuroectodermal Tumors / diagnosis. Neuroectodermal Tumors / therapy. Poland / epidemiology. Retrospective Studies. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / therapy. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738590.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


12. Handa U, Chhabra S, Mohan H: Aspiration cytology of extramammary tumours metastatic to the breast. Indian J Pathol Microbiol; 2007 Oct;50(4):855-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was undertaken to highlight the use of fine needle aspiration cytology (FNAC) to distinguish tumours metastatic to the breast from primary breast malignancies.
  • The metastatic tumors included, 2 cases of malignant melanoma (chest wall and left arm), 1 case each of haematolymphoid malignancy, adenocarcinoma of the ovary, and squamous cell carcinoma (left leg).
  • FNA diagnosis of metastasis to the breast is essential in order to avoid unnecessary mastectomy and to ensure appropriate chemotherapy and/or irradiation treatment.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306588.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


13. Gale J, Mead GM, Simmonds PD: Management of spinal cord and cauda equina compression secondary to epidural metastatic disease in adults with malignant germ cell tumours. Clin Oncol (R Coll Radiol); 2002 Dec;14(6):481-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of spinal cord and cauda equina compression secondary to epidural metastatic disease in adults with malignant germ cell tumours.
  • METHODS: Clinical data regarding presenting history, physical examination, staging investigations, treatment and clinical outcome were retrospectively obtained from patient records.
  • RESULTS: Eight patients exhibited neurological deficits at the time of initial presentation of germ cell cancer or as a first manifestation of relapse following dog leg irradiation.
  • Four of these cases were managed with chemotherapy alone, with excellent neurological recovery, whilst four underwent decompressive laminectomy--in three cases prior to referral and in one case after commencing chemotherapy.
  • Four required further chemotherapy (high dose in two cases).
  • Two patients presented with cord compression as a feature of disease relapse following chemotherapy, and were managed with radiotherapy alone in an attempt to achieve local disease control and limit neurological dysfunction.
  • [MeSH-major] Bone Neoplasms / secondary. Cauda Equina / pathology. Neoplasms, Germ Cell and Embryonal / secondary. Peripheral Nervous System Neoplasms / secondary. Spinal Cord Compression / etiology. Spinal Cord Compression / therapy. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Physical Examination. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12512971.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Stephenson AJ: Current treatment options for clinical stage I seminoma. World J Urol; 2009 Aug;27(4):427-32
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment options for clinical stage I seminoma.
  • Adjuvant radiotherapy, surveillance, and single-agent carboplatin chemotherapy are all accepted treatment options for clinical stage (CS) I seminoma with cure rates approaching 100%.
  • Low-dose (25-35 Gy) adjuvant radiotherapy to the retroperitoneum and ipsilateral pelvis has been the mainstay of treatment for decades and is associated with excellent long-term survival and acceptable short-term toxicity.
  • The use of lower radiation doses (20 Gy) and the omission of pelvic radiation have been investigated to reduce toxicity.
  • However, the risk of late toxicity (specifically cardiovascular disease and secondary malignant neoplasms) resulting from radiation exposure have diminished the appeal of this approach, particularly given the fact that 80-85% of patients are cured by orchiectomy.
  • The appeal of surveillance is the avoidance of treatment-related morbidity in 80-85% of patients and the successful salvage of relapses with 30-35 Gy radiotherapy in most cases.
  • However, given the prolonged time course to relapse in CS I seminoma on surveillance, long-term follow-up with frequent abdominal-pelvic imaging is required.
  • However, concerns about the risk of inadequate therapy and late toxicity limit the acceptance of this approach until long-term results are available.
  • With potential of avoiding treatment-related toxicity without compromising curability and given the overall low risk of occult metastasis in clinical stage I seminoma, surveillance is the recommended treatment option.
  • Adjuvant dog-leg radiotherapy is the preferred approach for non-compliant patients or those unwilling to go on surveillance.
  • [MeSH-major] Seminoma / drug therapy. Seminoma / radiotherapy. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Combined Modality Therapy. Humans. Male. Neoplasm Staging. Population Surveillance. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):640-7 [14726503.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1310-5 [17416851.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):293-300 [16039331.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2277-84 [18046031.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):3-8 [8175442.001]
  • [Cites] Urology. 2002 Aug;60(2):324-8 [12137835.001]
  • [Cites] J Urol. 2005 Mar;173(3):824-9 [15711278.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):101-4 [11134201.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2305-11 [15150576.001]
  • [Cites] APMIS. 2003 Jan;111(1):76-83; discussion 83-5 [12752240.001]
  • [Cites] Eur J Cancer. 1993;29A(14):1931-4 [8280484.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8717-23 [16260698.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):867-72 [12796024.001]
  • [Cites] Br J Cancer. 1992 May;65(5):775-8 [1586607.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2255-62 [7666083.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5524-9 [18936477.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):736-40 [15708251.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1146 [10561173.001]
  • [Cites] Urology. 2000 Jan;55(1):102-6 [10654903.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1200-8 [15718317.001]
  • [Cites] Eur J Cancer. 2002 Jan;38(1):11-6 [11750834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):383-8 [2921142.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4448-52 [12431967.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4370-8 [17906202.001]
  • [Cites] Can J Urol. 2002 Oct;9(5):1637-40 [12431325.001]
  • (PMID = 19370354.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


15. Altmann S, Lenz-Scharf O, Schneider W: [Therapeutic options for aggressive fibromatosis]. Handchir Mikrochir Plast Chir; 2008 Apr;40(2):88-93
Genetic Alliance. consumer health - Fibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options for aggressive fibromatosis].
  • INTRODUCTION: Aggressive fibromatosis, e.g., desmoid tumour, is a rare neoplasm of the connective tissue with local infiltrative growth.
  • Because of the high recurrence rates and destruction of the surrounding tissue, these tumours are classified as semi-malignant.
  • Radical surgical treatment with tumour excision accompanied by radiotherapy is the current standard therapy that can be supplemented by pharmacological treatment in a few cases.
  • PATIENTS AND METHOD: We report on 9 patients (5 males and 4 females) with surgical therapy for aggressive fibromatosis.
  • The neoplasm was located on the extremities in 7 cases (4 x upper extremity, 3 x lower extremity), one tumour was situated in the chin and one in the rectus abdominis muscle.
  • In these cases, an adjuvant radiotherapy with 25 x 2 Gy was started postoperatively after the accomplished wound healing.
  • Treatment with chemotherapeutic agents was not necessary.
  • DISCUSSION: Aggressive fibromatosis is a semimalignant neoplasm of the connective tissue with an extremely high recurrence rate.
  • Therapy of choice is the radical surgical resection.
  • Pharmacological treatment should be considered for patients with unsuccessful local therapy.
  • [MeSH-major] Fibromatosis, Aggressive / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Arm. Chin. Female. Follow-Up Studies. Humans. Leg. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant. Rectus Abdominis. Surgical Flaps. Time Factors

  • Genetic Alliance. consumer health - Aggressive Fibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437666.001).
  • [ISSN] 0722-1819
  • [Journal-full-title] Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe : Organ der Vereinigung der Deutschen Plastischen Chirurgen
  • [ISO-abbreviation] Handchir Mikrochir Plast Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Bula P, Bula-Sternberg J, Wollina U, Haroske G, Bonnaire F: [Marjolin's ulcer: malignant transformation of a crural ulcer due to posttraumatic chronic osteomyelitis]. Unfallchirurg; 2010 Feb;113(2):149-54
MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Marjolin's ulcer: malignant transformation of a crural ulcer due to posttraumatic chronic osteomyelitis].
  • We report on the case of an 81-year-old female patient who developed a squamous cell carcinoma in a long-lasting therapy-resistant crural ulcer of the lower leg due to posttraumatic chronic osteomyelitis.
  • Eventually the lower leg had to be amputated because of massive destruction of soft tissue and the tibia bone.
  • [MeSH-major] Amputation. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Cell Transformation, Neoplastic / pathology. Leg Injuries / pathology. Leg Injuries / surgery. Leg Ulcer / pathology. Leg Ulcer / surgery. Osteomyelitis / pathology. Osteomyelitis / surgery. Pseudomonas Infections / pathology. Pseudomonas Infections / surgery. Pseudomonas aeruginosa. Skin Ulcer / pathology. Tibia / surgery. Wounds, Penetrating / pathology. Wounds, Penetrating / surgery
  • [MeSH-minor] Aged, 80 and over. Artificial Limbs. Chronic Disease. Disease Progression. Drug Resistance, Bacterial. Female. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Skin / pathology

  • Genetic Alliance. consumer health - Osteomyelitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 1999 May;(362):181-9 [10335297.001]
  • [Cites] J South Orthop Assoc. 1999 Fall;8(3):181-7 [12132863.001]
  • [Cites] Rev Rhum Engl Ed. 1996 Jan;63(1):62-4 [9064114.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 Jul;6(7):569-72 [18248496.001]
  • [Cites] Br J Dermatol. 1995 Oct;133(4):571-4 [7577586.001]
  • [Cites] Acta Orthop Belg. 1993;59(4):327-32 [8116362.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Aug;21(7):935-41 [17659003.001]
  • [Cites] Adv Dermatol. 1987;2:19-46 [3079255.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Med J Aust. 1996 Jun 17;164(12):718-20 [8668077.001]
  • [Cites] South Med J. 2005 Oct;98(10):1053 [16295826.001]
  • [Cites] Dermatol Online J. 2007 May 01;13(2):27 [17498446.001]
  • [Cites] Indian J Cancer. 1996 Sep;33(3):139-44 [9055488.001]
  • [Cites] J Burn Care Rehabil. 1990 Sep-Oct;11(5):460-9 [2246317.001]
  • [Cites] Int J Dermatol. 1991 Jan;30(1):58-61 [1993569.001]
  • [Cites] Int Orthop. 2001;25(6):389-91 [11820449.001]
  • [Cites] J Foot Surg. 1981 Fall;20(3):136-41 [7276451.001]
  • [Cites] J Bone Joint Surg Am. 1990 Jan;72(1):12-8 [2295659.001]
  • [Cites] J Clin Pathol. 1963 Nov;16:573-80 [14076377.001]
  • [Cites] Ann Dermatol Venereol. 1993;120(10):675-8 [8161096.001]
  • [Cites] Orthop Rev. 1991 Jul;20(7):625-8 [1945509.001]
  • [Cites] Ann Surg. 1981 May;193(5):598-605 [7235765.001]
  • [Cites] J Dermatol Surg Oncol. 1994 Feb;20(2):141-3 [8113507.001]
  • [Cites] J Mal Vasc. 2001 Apr;26(2):85-91 [11319413.001]
  • [Cites] Clin Orthop Relat Res. 1985 Sep;(198):264-7 [4028559.001]
  • [Cites] Dermatol Surg. 1996 Dec;22(12):1015-8 [9078313.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):235-41 [1734084.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 2007 Feb;93(1):63-71 [17389826.001]
  • [Cites] Skeletal Radiol. 2001 Jun;30(6):331-7 [11465774.001]
  • [Cites] Arch Phys Med Rehabil. 1986 Nov;67(11):831-3 [3778183.001]
  • (PMID = 19859679.001).
  • [ISSN] 1433-044X
  • [Journal-full-title] Der Unfallchirurg
  • [ISO-abbreviation] Unfallchirurg
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Lejeune FJ, Pujol N, Liénard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot PG, Chiolero R, Bischof-Delaloye A, Leyvraz S, Mirimanoff RO, Bejkos D, Leyvraz PF: Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol; 2000 Nov;26(7):669-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
  • AIMS: Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation.
  • In order to avoid major amputations, we tested isolated limb perfusion (ILP) with tumour necrosis factor alpha (TNF)+melphalan+/-interferon-gamma (IFN) as a pre-operative, neoadjuvant limb salvage treatment.
  • Thirteen cases were recurrent or progressive after previous therapy; five tumours had a diameter >/=20 cm, and four were multiple or regionally metastatic.
  • There were six malignant fibrous histiocytomas, five liposarcomas, four malignant peripheral nerve sheath tumours, three rhabdomyosarcomas, two leiomyosarcomas, one recurrent extraskeletal osteosarcoma and one angiosarcoma.
  • All patients had fever for 24 hours but only one developed a reversible grade 3 distributive shock syndrome with no sequelae.
  • Seventeen patients (77%) underwent limb-sparing resection of the tumour remnants after a median time of 3.4 months: 10 resections were intracompartmental and seven extracompartmental.
  • Adjuvant chemotherapy was given to eight patients and radiotherapy to six.
  • The median disease free and overall survival times have been >12.5 and 18.7 months respectively: this is similar to the outcome after primary amputations for similar cases.
  • CONCLUSION: ILP with TNF and chemotherapy is an efficient limb sparing neoadjuvant therapy for a priori non-resectable limb soft tissue sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leg / surgery. Sarcoma / drug therapy. Sarcoma / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Chemotherapy, Cancer, Regional Perfusion. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Interferon-gamma / administration & dosage. Interferon-gamma / adverse effects. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Salvage Therapy. Survival Analysis. Tumor Necrosis Factor-alpha / administration & dosage. Tumor Necrosis Factor-alpha / adverse effects

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 11078614.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 80168379AG / Doxorubicin; 82115-62-6 / Interferon-gamma; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


18. Fink W, Zimpfer A, Ugurel S: Mucosal metastases in malignant melanoma. Onkologie; 2003 Jun;26(3):249-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal metastases in malignant melanoma.
  • BACKGROUND: We present the case of a patient with malignant melanoma stage IV according to the American Joint Committee on Cancer (AJCC) classification and an unusual pattern of metastasis to the mucosa of the esophagus, the stomach, the bladder and the palatine tonsil.
  • CASE REPORT: A 38-year-old male patient with metastatic malignant melanoma of stage III (AJCC) was admitted for initiation of adjuvant therapy.
  • 4 months earlier a primary melanoma of the left upper leg had been excised and 2 months later the patient had undergone a left inguinal lymph node dissection revealing 2 metastatic lymph nodes.
  • Two cycles of dacarbazine (DTIC) chemotherapy were performed during which the patient developed cutaneous metastases, dyspepsia, and mild hematemesis.
  • A few weeks later the patient developed macroscopic hematuria.
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Gastric Mucosa / pathology. Humans. Male. Mucous Membrane / pathology. Neoplasm Staging. Tomography, Emission-Computed


19. Busam KJ, Hester K, Charles C, Sachs DL, Antonescu CR, Gonzalez S, Halpern AC: Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy. Arch Dermatol; 2001 Jul;137(7):923-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy.
  • OBJECTIVES: To investigate the feasibility of detecting a clinically amelanotic malignant cutaneous melanoma using CSLM and to explore the use of this technique for assessing its margins.
  • CONCLUSIONS: We demonstrated, for the first time, the detection of clinically amelanotic melanoma using CSLM.
  • This technique may aid in the early detection of clinically barely visible or nonpigmented melanomas and may facilitate preoperative noninvasive assessment of their margins.
  • [MeSH-minor] Aged. Biopsy. Cheek. Female. Humans. Immunohistochemistry. Infrared Rays. Leg. Melanosomes / pathology. Microscopy, Electron. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11453812.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Siebenrock KA, Hertel R, Ganz R: Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery. Arch Orthop Trauma Surg; 2000;120(1-2):65-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery.
  • Sixteen referred patients were reviewed after excision of an unexpected soft-tissue sarcoma of the extremities.
  • The lack of awareness by the primary physician towards the possibility of a malignant lesion was striking, although 11 of 16 tumors presented as a newly formed mass.
  • Four patients received adjuvant local radiation, with additional chemotherapy in 2 of them.
  • At an average follow-up of 4.5 years (range 15-149 months), 4 patients (25%) had developed distant metastases with a local recurrence in 3 (19%).
  • Evaluation by adequate imaging techniques, biopsy, and definitive resection and reconstruction should be performed by an oncologically trained orthopaedic surgeon.
  • Inadequate primary excision leads to a high local recurrence rate and more mutilating surgery and obscures the long-term prognosis.
  • [MeSH-major] Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Amputation. Chemotherapy, Adjuvant. Female. Forearm. Humans. Leg. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Reoperation. Shoulder

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10653107.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


21. Christensen NR, Charabi S, Johansen LS, Rygaard J, Balle VH, Tos M, Thomsen J: Effect of photodynamic therapy on a heterotransplanted human parotid tumor. Auris Nasus Larynx; 2000 Jul;27(3):241-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of photodynamic therapy on a heterotransplanted human parotid tumor.
  • To evaluate the effect of photodynamic therapy on human parotid tumors we used tumor specimens obtained from parotid surgery on a consecutive group of patients.
  • We re-implanted this tumor on ten mice bilaterally, and treated the tumors with photodynamic therapy (PDT), resulting in a mean depth of tumor necrosis of 5.4 mm (1-10 mm).
  • In three cases we found vital tumor cells in the periphery of the tumor after treatment, with several new blood vessels in the surrounding tissue, indicating a great potential for neo-angiogenesis in this tumor.
  • In order to evaluate the possible nerve damage subsequent to the photodynamic therapy, the ischiadic nerve in 24 lower limbs of nude mice were investigated.
  • The current study demonstrates that the nude mice implantation model is excellent to investigate growth in both malignant and benign parotid tumors, and to test new therapeutic modalities.
  • Photodynamic therapy seems to have a possible role in the future management of the malignant lesions of the parotid gland, in cases where radical surgery for some reason is not achievable.
  • [MeSH-major] Neoplasm Transplantation. Parotid Neoplasms / drug therapy. Photochemotherapy. Transplantation, Heterologous
  • [MeSH-minor] Animals. Female. Humans. Leg / innervation. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Necrosis. Neovascularization, Pathologic / pathology. Nervous System / pathology. Postoperative Period

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10808112.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NETHERLANDS
  •  go-up   go-down






Advertisement